News Column

Patent Issued for Method for Proliferating Stem Cells by Activating c-MET/HGF Signaling and Notch Signaling

September 11, 2014



By a News Reporter-Staff News Editor at Gene Therapy Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Nam, Do Hyun (Sungnam-si, KR); Hong, Seung Chyul (Seoul, KR); Kang, Bong gu (Seoul, KR); Joo, Kyeung Min (Seoul, KR), filed on February 1, 2011, was published online on August 26, 2014 (see also Samsung Life Public Welfare Foundation).

The assignee for this patent, patent number 8815581, is Samsung Life Public Welfare Foundation (Seoul, KR).

Reporters obtained the following quote from the background information supplied by the inventors: "Biotechnology in the 21.sup.st century presents the possibility of new solutions to food, environmental and health problems, with the ultimate object of promoting human prosperity. In recent years, the technology of using stem cells has been considered as a new way to treat incurable diseases. Previously, organ transplantation, gene therapy, etc., were presented for the treatment of incurable human diseases, but their efficient use has not been achieved due to immune rejection, short supply of organs, insufficient development of vectors, and an insufficient knowledge of disease genes.

"With increasing interests in stem cell studies, it has been recognized that totipotent stem cells having the ability to form all the organs by proliferation and differentiation can not only treat most of diseases but also fundamentally heal organ injuries. Stem cells refer to cells having not only self-replication ability but also the ability to differentiate into at least two cells, and can be divided into totipotent stem cells, pluripotent stem cells, and multipotent stem cells. Many scientists have suggested clinical applicability of stem cells for the regeneration of all the organs and the treatment of incurable diseases, including Parkinson's disease, various cancers, diabetes and spinal damages.

"Particularly, neural stem cells are capable of self-renewal and have the potential to differentiate into three major cell types of the central nerve system, including neurons, astrocytes, and oligodendrocytes. Accordingly, interests in neural stem cells are increasing recently, not only with regard to basic researches on mechanisms of proliferation and differentiation of stem cells and development of nervous systems, but also with regard to the possibility of new cell and gene therapy in neurological diseases, which are known not to be regulated once damaged, utilizing biological characteristics of the neural stem cells.

"The concept that stem cells require specific cellular microenvironments, or niches, for their culture, is a well-established theory in stem cell biology. As techniques for selectively culturing neural stem cells, neurosphere formation, low-density culture, and high-density culture, etc., were reported, but it is known to be difficult to expand cells in large-scale culture in an undifferentiated state.

"Several researchers have attempted the large-scale culture of stem cells. However, human adult neural stem cells are particularly difficult to culture in vitro and also have limited ability to proliferate. For this reason, studies on human adult neural stem cells are at a standstill.

"Accordingly the present inventors have conducted studies to overcome the problem of the limited ability of human adult neural stem cells to proliferate, and as a result, have found that, when primarily cultured adult neural stem cells are cultured after genes that can activate the signaling pathways in the neural stem cells have been transfected into the neural stem cell, the ability of the neural stem cells to proliferate is significantly increased, thereby completing the present invention."

In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "It is an object of the present invention to provide stem cells in which a gene that activates Notch signaling is introduced, and thus have an excellent ability to proliferate, and a method for producing the stem cells.

"Another object of the present invention is to provide a cell therapeutic agent for treating cranial nerve disease, which comprises neural stem cells in which the NICD (Notch intracellular domain) gene is introduced, as an active ingredient.

"Still another object of the present invention is to provide stem cells, in which the c-MET gene is introduced and, either in which the HGF (hepatocyte growth factor)-encoding gene is introduced or which are treated with HGF to activate the c-MET/HGF signaling pathway, and a method for proliferating the stem cells.

"Still another object of the present invention is to provide a cell therapeutic agent for treating cranial nerve disease, which comprises neural stem cells in which the c-MET gene is introduced as an active ingredient.

"Still another object of the present invention is to provide an use of the neural stem cells transfected with the NICD gene for treating or preventing cranical nerve disease.

"To achieve the above objects, the present invention provides stem cells having an excellent ability to proliferate, in which a gene that activates Notch signaling is introduced, and a method for proliferating stem cells, the method comprising a step of culturing stem cells transfected with a gene that activates Notch signaling.

"The present invention also provides a cell therapeutic agent for treating cranial nerve disease, which comprises neural stem cells or neural crest stem cells in which the NICD (Notch intracellular domain) gene is introduced and Notch signaling is activated, as an active ingredient.

"The present invention also provides stem cells having excellent abilities to proliferate, in which the c-MET gene is introduced and, either a HGF (hepatocyte growth factor)-encoding gene is introduced or which are treated with HGF to activate the c-MET/HGF signaling pathway, and a method for proliferating stem cells in which the c-MET/HGF signaling pathway is activated.

"The present invention also provides a cell therapeutic agent for treating cranial nerve disease, which comprises neural stem cells or neural crest stem cells in which the c-MET/HGF signaling pathways are activated, as an active ingredient.

"Other features and embodiments of the present invention will be more apparent from the following detailed descriptions and the appended claims."

For more information, see this patent: Nam, Do Hyun; Hong, Seung Chyul; Kang, Bong gu; Joo, Kyeung Min. Method for Proliferating Stem Cells by Activating c-MET/HGF Signaling and Notch Signaling. U.S. Patent Number 8815581, filed February 1, 2011, and published online on August 26, 2014. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8815581.PN.&OS=PN/8815581RS=PN/8815581

Keywords for this news article include: Bioengineering, Biotechnology, Gastroenterology, Gene Therapy, Samsung Life Public Welfare Foundation, Stem Cell Research, Therapeutics.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters